Biomarker-Directed Phase II Platform Study in Patients With EGFR Sensitizing Mutation-Positive Advanced/Metastatic Non-Small Cell Lung Cancer Whose Disease Has Progressed on First-Line Osimertinib Therapy (ORCHARD)Helena A. Yu, Jonathan W. Riess, Jonathan W. Goldman et al.|Clinical Lung Cancer|2021Cited by 73
1239P ORCHARD osimertinib + savolitinib interim analysis: A biomarker-directed phase II platform study in patients (pts) with advanced non-small cell lung cancer (NSCLC) whose disease has progressed on first-line (1L) osimertinibHelena A. Yu, Xiuning Le, Helen Ambrose et al.|Annals of Oncology|2021Cited by 47